SNOA AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
SNOA Current Performance
-7.28%
Sonoma pharmaceuticals inc
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to SNOA
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
BIAF | Bioaffinity technologies inc | - | 4 | 3 | 1 | 1 | |
SINT | Sintx technologies inc | 3 | 1 | 4 | 1 | 1 | |
DRIO | Dariohealth corp | 3 | 2 | 2 | 1 | 1 | |
KIDS | Orthopediatrics corp | 3 | 4 | 2 | 2 | 1 | |
ACON | Aclarion inc | - | 3 | 2 | 1 | 1 |
- BIAF Bioaffinity technologies incValue -Trend 4Swing Trading 3Whale Interest 1Dividend 1See more
SNOA Profile
Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.